An Open Label Study on the Effects of a Short Course of SB480848 (Darapladib) on Contents of Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs Darapladib (Primary)
- Indications Atherosclerosis
- Focus Biomarker; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 16 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.